Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy

  • days left to enroll
  • participants needed
  • sponsor
    RenJi Hospital
Updated on 24 January 2021
absolute neutrophil count
breast cancer
endocrine therapy
neutrophil count
hormone therapy
advanced breast cancer
locally advanced breast cancer
adjuvant chemotherapy


This trial will compare the administration of 2 cycles of paclitaxel and cisplatin (DP) versus 4 cycles of CEF as adjuvant chemotherapy for the patients with locally advanced breast cancer and who were pathological partial response to DP as neoadjuvant chemotherapy. Those who had pathological complete response to DP will be randomized to have 2 cycles of DP or have no further chemotherapy.


All the patients who had neoadjuvant chemotherapy and had pathological complete response (pCR) or partial response to DP will enrolled in this trial. Those who had pCR will randmized to have two cycles of DP as adjuvant chemotherapy or have no further chemotherapy. Those patients who had PR will be randomized to have two cycles of DP or four cycles of CEF. All the patients with hormonal receptor positive or Her2 overexpress tumors are allowed to accept endocrine therapy or anti-Her2 target therapy.

Condition Invasive Ductal Breast Carcinoma, Breast Cancer, Breast Cancer, Inflammatory Breast Cancer, Tubular Breast Cancer, Mucinous Breast Cancer, inflammatory breast cancers
Treatment cyclophosphamide, cisplatin, Epirubicin, Paclitaxel, 5-fluoruracil
Clinical Study IdentifierNCT02879513
SponsorRenJi Hospital
Last Modified on24 January 2021


Yes No Not Sure

Inclusion Criteria

Women aged 18years and 70 years
Patients with locally advanced breast caner and had weekly paclitaxel and cisplatin as neoadjuvant chemotherapy
Patients with pathological partial response or pathological complete response to neoadjuvant chemotherapy according to the Response Evaluation Criteria in Solid Tumors (RECIST)
Endocrine therapy and trastuzumab were allowed to use
ECOG 0-2
Adequate bone marrow function:WBC4.0109/L, Absolute neutrophil countANC1.5109/L, PlateletsPLT100109/L, HemoglobinHb90g/L;aspartate aminotransferase(AST),Alanine aminotransferase (ALT)1.5 upper normal limit (UNL), creatinine1.5 UNL, bilirubin1.5UNL
No obvious main organs dysfunction

Exclusion Criteria

Unwilling or unable to use an acceptable method of contraception in 8 weeks (including 8 weeks) after final dose of test drug
Patient is pregnant or breast feeding
Metastatic breast cancer
Any evidence of sense or motor nerve disorders
Patients with medical conditions taht indicate intolerant to neoadjuvant therapy, including uncontrolled cardiovascular disease, severe infection
Any concurrent malignancy other than breast cancer
Know severe hypersensitivity to any drugs in this study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note